MEDICAMEN Organics Limited
Regd. & Corporate Office: 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
Tel: 011-27430249, 27138171
E-mail: info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | **GSTIN:**07AABCM4302P1ZF

June 3, 2025

To,
National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai, Maharashtra, 400051, India

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Dear Sir / Madam,

Subject: Press Release - Audited Financial Results of the Company for the Half Year and Year ended March 31, 2025.

In pursuance of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform all our stakeholders that the Company has announced the Audited financial results for the half year and year ended March 31, 2025. The Press release with reference to the same is enclosed herewith.

You are requested to take note of the same.

Thanking You.

Yours faithfully,
For **Medicamen Organics Limited**

Ashutosh Gupta
Digitally signed by Ashutosh Gupta
Date: 2025.06.03 19:30:05 +05'30'

Ashutosh Gupta
Whole-time director
DIN: 00039995

Place: New Delhi

Encl.: as stated above

PRESS RELEASE

Year Ended 31st March 2025

New Delhi, June 3, 2025

Medicamen Organics Limited

Revenue from Operations up by 51% YoY to ₹3818.77 lakhs
PAT growth of 101% YoY in H2FY25
Net Worth rose ~100% YoY to ₹3,048.07 lakhs in FY25

Consolidated Figures:

Particulars (₹ In Lakhs)	FY25	FY24	YoY
Revenue from operations	3818.77	2527.17	51.11%
EBIDTA	668.07	475.56	40.48%
Profit After Tax	404.71	262.43	54.22%
PAT Margin (%)	10.60%	10.38%	↑
Net Worth	3,048.07	1,525.94	99.75%
EPS (₹)	2.19	1.52	44.08%

Particulars (₹ In Lakhs)	H2 FY25	H2 FY24	YoY
Revenue from operations	2157.72	1395.17	54.66%
EBIDTA	390.64	234.41	66.65%
EBITDA Margin	18.06%	16.79%	↑
Profit After Tax	253.64	126.18	101.01%
PAT Margin (%)	11.76%	9.04%	↑
EPS (₹)	3.67	3.47	5.76%

Highlights

- Revenue increased due to a significant export presence in African, CIS, and Southeast Asian countries, being registered in 13 countries.
- Medicamen Organics Limited has identified significant market potential in:
  Rising consumer preference for natural, science-backed, and ethically produced beauty products Increasing demand across Tier I and II cities for gender-neutral and inclusive personal care
  The convergence of beauty, wellness, and lifestyle, offering cross-category synergies
- Global footprint and a strategic focus on expanding their international market presence.
- Manufacturing a wide range of pharmaceutical dosage forms including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.
- Strong relationships with customers and repeat orders. A loyal customer base and recurring business contribute to consistent and growing revenue streams.

Reflecting on the company's FY25 performance, Mr. Bal Kishan Gupta, Chairman and Managing Director of Medicamen Organics Limited, stated: "We are pleased to announce our formal entry into the cosmetics and personal care industry, through our subsidiary Grande Etiole Pharmaceuticals Limited, marking a significant milestone in its long-term growth and our diversification strategy. Our product portfolio consists of 84 products. We operate under different brand names across the globe. Our business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry. In terms of geographical diversity, we have marked our presence in India and we have registrations for manufacturing products as approved in international markets in countries like Congo, Benin, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan, Kenya. Our diversified revenue base enables us to mitigate the risk of income concentration by spreading revenue across multiple sources and opens opportunities to new prospects of growth."

About Medicamen Organics Limited

Medicamen Organics Limited is an Indian pharmaceutical company with a history dating back to 1995. It was initially incorporated on March 15, 1995, as **Panchdeep Pharmaceuticals Limited**.

The company's name was subsequently changed to **Medicamen Organics Limited** on November 14, 1995. In 2007, they began constructing their own manufacturing unit (Unit I) in Haridwar, which later received WHO/GMP certification.

Medicamen Organics is engaged in the development, manufacturing, and distribution of a broad range of pharmaceutical dosage forms. This includes generic dosages in various forms like tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders**.**

In 2024, they informed the exchange about the acquisition of Depot Pharmacy Yego Ltd.

For Further Information Please Contact:

Company: Medicamen Organics Limited	**Investor Relations:** EquiBridgeX Advisors Private Limited
Medicamen Organics Limited cs@mediorganics.in www.medicamenorganics.com	**EquiBridgeX Advisors Private Limited** Ms. Pooja Gandhi info@equibridgex.com www.equibridgex.com